Loading clinical trials...

Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus | Clinical Trials | Clareo Health

COMPLETEDNA

Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus

Plasma Glucose and Insulin Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus

NCT02898766•Société des Produits Nestlé (SPN)

Summary

This will be a randomized, cross-over design. Subjects will be randomized to one of two interventions on two separate study days, 1 week apart.

Eligibility

Age

20 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 20-75 yrs
•Type 2 diabetes controlled with diet or diet and oral agent, with the exception of sulfonylureas such as glimepiride (Amaryl), glipizide, Glucotrol/GlucotrolXL) and glyburide (DiaBeta, Micronase, (Glynase Prestabs); meglitinides such as reaglinide (Prandin) and nateglinide (Starlix); and alphaglucosidase inhibitors such as acarbose (Precose) and miglitol (Glyset)
•Hemoglobin A1C less than 9.0%
•Fasting blood glucose less than 180 mg

Exclusion Criteria

•Abnormal thyroid function
•Creatinine \>2.0 mg/dL
•Potassium \<3.5 mEq/L
•Gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting
•History of bypass surgery, midface trauma, esophageal varices, coagulation abnormalities
•Patients currently on any anti-coagulant medication
•Currently unstable diabetes or under treatment for cancer, heart disease, renal disease
•Unable to give informed consent or follow instructions
•Current insulin therapy or insulin therapy within the past month
•Patient who are pregnant
+3 more criteria

Locations (1)

Orange County Research Center

Tustin, California, United States

Key Dates

Start Date

August 1, 2016

Primary Completion Date

October 1, 2016

Completion Date

October 1, 2016

Last Updated

October 11, 2016

Enrollment

ACTUAL participants

Conditions

Diabetes

Interventions

Enteral Nutrition Formula

OTHER

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITING

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 11, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Genetic Studies of Insulin and Diabetes

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes